EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects

Hyun Chul Kim iD, Sangmi Lee iD, Siyoung Sung iD, Eunjin Kim iD, In-Jin Jang iD, Jae-Yong Chung iD

Drug Design, Development and Therapy · 2023

DOI: 10.2147/dddt.s404182 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Hyun Chul Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Prodrugs, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dapagliflozin formate (DAP-FOR, DA-2811), an ester prodrug of dapagliflozin, was developed to improve the stability and pharmaceutical manufacturing process of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor.

Purpose

This study aimed to evaluate the pharmacokinetics (PKs) and safety of dapagliflozin for DAP-FOR compared to those for dapagliflozin propanediol monohydrate (DAP-PDH, Forxiga) in healthy subjects.

Methods

This was an open-label, randomized, single-dose, two-period, two-sequence crossover study. The subjects received a single dose of DAP-FOR or DAP-PDH 10 mg in each period, with a 7-day washout. Serial blood samples for PK analysis were collected up to 48 hours after a single administration to determine plasma concentrations of DAP-FOR and dapagliflozin. PK parameters were calculated using a non-compartmental method and compared between the two drugs.

Results

In total, 28 subjects completed the study. DAP-FOR plasma concentrations were not detected in all of the blood sampling time points except for one time point in one subject, and the corresponding DAP-FOR plasma concentration in the subject was close to the lower limit of quantification. The mean plasma concentration-time profiles of dapagliflozin were comparable between the two drugs. The geometric mean ratios and its 90% confidence intervals of the maximum plasma concentration and area under the plasma concentration-time curve of dapagliflozin for DAP-FOR to DAP-PDH were within the conventional bioequivalence range of 0.80-1.25. Both drugs were well-tolerated, with a similar incidence of adverse drug reactions.

Conclusion

The rapid conversion of DAP-FOR into dapagliflozin led to the extremely low exposure of DAP-FOR and comparable PK profiles of dapagliflozin between DAP-FOR and DAP-PDH. The safety profiles were also similar between the two drugs. These results suggest that DAP-FOR can be used as an alternative to DAP-PDH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsHealthy VolunteersCross-Over StudiesTherapeutic EquivalencyFormatesPropylene GlycolsArea Under CurveBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

clinical trialdapagliflozinpharmacokineticsphase Iprodrugs

Substanzen

Hypoglycemic AgentsProdrugsSodium-Glucose Transporter 2 InhibitorsFormatesPropylene GlycolsdapagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
  • Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
  • Dong-A ST Research Institute, Yongin-si, Gyeonggi-do, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Hyun Chul Kim, Sangmi Lee, Siyoung Sung, Eunjin Kim, In-Jin Jang, Jae-Yong Chung

Zitieren

APA

Kim, H. C., Lee, S., Sung, S., Kim, E., Jang, I. J., & Chung, J. Y. (2023). A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s404182

Vancouver

Kim HC, Lee S, Sung S, Kim E, Jang IJ, Chung JY. A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s404182

BibTeX
@article{Kim2023,
  author = {Kim, Hyun Chul and Lee, Sangmi and Sung, Siyoung and Kim, Eunjin and Jang, In-Jin and Chung, Jae-Yong},
  title = {A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  doi = {10.2147/dddt.s404182}
}
Kostenlos starten →